Sort:
Clinical Research Issue
Intervention effects of supplementing a stereospecific structured lipid composition on lipid profile in patients with mild hyperlipidemia: a randomized controlled clinical trival
Chinese Journal of Multiple Organ Diseases in the Elderly 2026, 25(2): 81-86
Published: 28 February 2026
Abstract PDF (757.2 KB) Collect
Downloads:0
Objective

To observe the lipid-modulating and anti-inflammatory effects of supplementing a stereospecific structured lipid composition in patients with mild hyperlipidemia.

Methods

This prospective randomized controlled trial enrolled 100 patients with mild hyperlipidemia from the First Medical Center of Chinese PLA General Hospital from March to June 2024. They were randomly divided into a stereospecific structured lipid composition group (intervention group) and a control group, with 50 patients in each group. The intervention group received stereospecific structured lipid capsules (3 capsules tid) alongside standardized lifestyle modifications (low-salt, low-fat diet and exercise guidance), and the control group received only lifestyle modifications. The intervention lasted for three months in both groups. After the intervention, the intake of the three major nutrients, body composition, blood biochemistry, and high-sensitivity C-reactive protein (hs-CRP) were compared between the two groups. SPSS 26.0 was used for statistical analysis. Data comparison between two groups was performed using t test, χ2 test or Fisher′s exact probability method depending on data type.

Results

A total of 95 patients completed the study, 47 in the intervention group and 48 in the control group. Baseline characteristics showed no statistically significant differences between the two groups (P>0.05). Post-intervention analysis revealed no statistically significant differences between the two groups in nutrient intake, body composition, and safety parameters (P>0.05), and in blood biochemical parameters including liver function, kidney function, blood glucose, and protein indicators (P>0.05). After the intervention, the levels of total cholesterol (TC) [(4.26±1.08) vs (5.79±1.12) mmol/L], low-density lipoprotein cholesterol (LDL-C) [(3.16±0.72) vs (4.45±0.62) mmol/L], non-high-density lipoprotein cholesterol (non-HDL-C) [(3.05±0.82) vs (3.70±0.96) mmol/L], hs-CRP [(0.57±0.23) vs (0.87±0.31) mg/dl], and hs-CRP/HDL-C [(0.47±0.22) vs (0.67±0.25)] in the intervention group were significantly lower than those before the intervention (P<0.05). In the control group, LDL-C was significantly lower after the intervention than before the intervention [(3.52±0.95) vs (4.60±0.58) mmol/L; P<0.05], while non-HDL-C was significantly higher [(4.78±0.63) vs (3.68±1.02) mmol/L; P<0.05]. The intervention group demonstrated significantly lower TG [(1.62±1.11) vs (2.21±1.32) mmol/L], LDL-C [(3.16±0.72) vs (3.52±0.95) mmol/L], non-HDL-C [(3.05±0.82) vs (4.78±0.63) mmol/L], hs-CRP [(0.57±0.23) vs (0.73±0.35) mg/dl], and hs-CRP/HDL-C [(0.47±0.22) vs (0.64±0.36)] than those in the control group (P<0.05).

Conclusion

Supplementing a stereospecific structured lipid composition improves blood lipid profiles and inflammation in patients with mild hyperlipidemia without adverse effects on hepatorenal function, playing a role in reducing the risk of atherosclerotic cardiovascular diseases.

Clinical Research Issue
Effects of individualized low-glycemic-index high-protein diet on glucose and lipid metabolism and body composition in male type 2 diabetes mellitus patients
Chinese Journal of Multiple Organ Diseases in the Elderly 2026, 25(8): 583-588
Published: 28 August 2026
Abstract PDF (443.7 KB) Collect
Downloads:2
Objective

To investigate the effects of an individualized low-glycemic-index (GI) high-protein diet based on an intelligent system on glucose and lipid metabolism and body composition in male patients with type 2 diabetes mellitus (T2DM), and to compare it with conventional dietary guidance.

Methods

A total of 103 male outpatients with T2DM who visited Department of Nutrition of First Medical Center, Chinese PLA General Hospital from January 2024 to June 2025 were enrolled, and based on their dietary pattern, they were divided into a study group (n=52, receiving an intelligent individualized low-GI high-protein diet) and a control group (n=51, receiving conventional dietary guidance). The intervention lasted 12 weeks. Anthropometric indicators, glucose metabolism indicators, lipid metabolism indicators, and liver and kidney functions were compared between two groups to evaluate the safety and efficacy of the intervention. SPSS statistics 26.0 was used for statistical analysis. Data comparison between two groups was performed using t test or χ2 test depending on data type.

Results

There were 103 patients completing the study, including 52 patients in the study group and 51 patients in the control group. After 12 weeks of intervention, body weight, waist circumference, hip circumference, and body fat percentage were significantly lower in the study group than the control group (P<0.05). The study group exhibited significantly lower fasting blood glucose [(6.18±0.95) vs (7.25±1.03 mmol/L], 2-h postprandial blood glucose [(7.25±1.52) vs (9.31±1.85) mmol/L], glycated hemoglobin [(6.2±0.6)% vs (7.1±0.6)%], and fasting insulin [(6.48±2.53) vs (7.79±2.85) mIU/L] compared to the control group (all P<0.05). In terms of lipid metabolism, triglycerides, total cholesterol, and low-density lipoprotein cholesterol in the study group were all notably lower than those in the control group (P<0.05), while there were no statistically significant differences in high-density lipoprotein cholesterol or serum uric acid between two groups (P>0.05). In liver and kidney function, no obvious differences were observed in serum creatinine and blood urea nitrogen before and after intervention between two groups (P>0.05), and all values were within the normal reference ranges.

Conclusion

The intelligent individualized low-GI high-protein diet pattern achieves personalized regulation of dietary intervention through an intelligent system, and can improve glucose and lipid metabolism disorders and optimize body composition in male patients with T2DM. It is safe for short-term application, superior to conventional dietary guidance, and has clinical promotion value.

Open Access CONSENSUS AND GUIDELINES Issue
Expert Consensus on Multidisciplinary Diagnosis and Treatment of Gastroparesis in China (2025, Beijing)
Advanced Ultrasound in Diagnosis and Therapy 2026, 10(1): 1-19
Published: 17 March 2026
Abstract PDF (835.7 KB) Collect
Downloads:249

Gastroparesis (GP) is a gastric motility disorder characterized by delayed gastric emptying in the absence of mechanical obstruction. This expert consensus covers aspects of GP etiology (diabetes, surgery, drug-induced, idiopathic, scleroderma, etc.), symptomatology, diagnosis (scintigraphic imaging, ultrasound contrast meal assessment, and radiopaque marker gastric motility testing), and treatment (pharmacological therapy, nutritional support, traditional Chinese medicine, and interventions targeting the pylorus, such as endoscopic surgery and surgical procedures). GP significantly impacts patients' psychological well-being and quality of life, potentially leading to psychological disorders such as anxiety and depression, and also imposes a heavy economic burden on patients and society. Therefore, this expert consensus advocates for the establishment of a multidisciplinary team diagnosis and treatment model, which will further standardize and optimize the diagnosis and treatment process of GP in our country and is crucial for improving patients' therapeutic outcomes and quality of life.

Open Access Just Accepted
Synergistic Effects of Omega-3 Fatty Acids and Coenzyme Q10 on Gut Microbiota-Mediated Lipid Metabolism in Borderline Dyslipidemia: A Single-center Randomized Open Labeled Controlled Clinical Trial
Food Science and Human Wellness
Available online: 17 March 2026
Abstract PDF (1.3 MB) Collect
Downloads:44

Background: Borderline dyslipidemia is a prevalent cardiovascular risk factor for which pharmacological intervention is not always indicated. Omega-3 polyunsaturated fatty acids and coenzyme Q10 (CoQ10)  have been reported to influence lipid metabolism and oxidative status; however, their combined effects in individuals with borderline dyslipidemia remain unclear. Objective: This study aimed to explore the associations of combined supplementation with α-linolenic acid (ALA) and CoQ10 with lipid metabolism, gut microbiota, and serum metabolites in patients with borderline dyslipidemia. Methods: In a 12-week, single-center randomized, open-label controlled trial, 90 participants with borderline dyslipidemia were assigned to receive either ALA (1.6 g/d) plus CoQ10 (136 mg/d) or standard dietary and exercise guidance alone. Primary outcomes included changes in serum lipids, lipoprotein subfractions (by NMR spectroscopy), gut microbiota (16S rRNA sequencing), and serum metabolomic profiles. Results:  Eighty-two participants completed the trial. Compared with the control group, the Omega-3_Q10 group showed significantly different change-from-baseline values in multiple lipid parameters, with mixed directions of change. Exploratory analyses identified concurrent changes in selected lipoprotein subfractions, gut microbiota composition, bile acid-related metabolites, and antioxidant markers. Conclusions:  Combined supplementation with ALA and CoQ10 was associated with short-term changes in lipid-related and metabolic markers in individuals with borderline dyslipidemia. Given the exploratory nature of the analyses, short intervention duration, and absence of clinical cardiovascular endpoints, the long-term clinical implications of these findings remain uncertain and warrant confirmation in larger, prospective studies with defined clinical outcomes.

Total 4